Y. Lu et al., Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603, BLOOD, 97(4), 2001, pp. 1123-1130
Acute graft-versus-host diseases(GVHD) is a major cause of morbidity and mo
rtality in patients undergoing allogeneic bone marrow transplantation (BMT)
. T helper 1 (Th1)-type cytokines such as interferon-gamma or tumor necrosi
s factor-iv have been implicated in the pathogenesis of acute GVHD. TAK-603
is a new quinoline derivative, which is now in clinical trials for use as
a disease-modifying antirheumatic drug. In preclinical studies, it inhibite
d delayed-type hypersensitivity, but not Arthus-type reaction, in mice, and
selectively suppressed Th1 cytokine production. Thus, the present study wa
s designed to investigate whether the Th1 inhibitor (TAK-603) ameliorates l
ethal acute GVHD in a mouse model. Administration of TAK-603 into BALB/c mi
ce given 10 Gy total body irradiation followed by transplantation of bone m
arrow and spleen cells from C57BL/6 mice markedly reduced the mortality in
association with minimal signs of GVHD pathology in the liver, intestine, a
nd skin. TAK-603 reduced not only the production of Th1-type cytokines, but
also the proportion of Th1 cells in CD4(+) helper T cells in this GVHD mou
se model. These results suggest that TAK-603 could be a potent therapeutic
agent for acute lethal GVHD.